Mural Oncology (MURA) Competitors $1.77 -0.02 (-1.12%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 08/14/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. FATE, BHST, CNTB, TARA, SPRO, OKYO, SAVA, CLYM, ALTS, and SKYEShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Fate Therapeutics (FATE), BioHarvest Sciences (BHST), Connect Biopharma (CNTB), Protara Therapeutics (TARA), Spero Therapeutics (SPRO), OKYO Pharma (OKYO), Cassava Sciences (SAVA), Climb Bio (CLYM), ALT5 Sigma (ALTS), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Its Competitors Fate Therapeutics BioHarvest Sciences Connect Biopharma Protara Therapeutics Spero Therapeutics OKYO Pharma Cassava Sciences Climb Bio ALT5 Sigma Skye Bioscience Fate Therapeutics (NASDAQ:FATE) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Do institutionals & insiders believe in FATE or MURA? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 2.2% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, FATE or MURA? Fate Therapeutics has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Do analysts recommend FATE or MURA? Fate Therapeutics presently has a consensus target price of $3.58, indicating a potential upside of 234.89%. Mural Oncology has a consensus target price of $12.00, indicating a potential upside of 577.97%. Given Mural Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Mural Oncology is more favorable than Fate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is FATE or MURA more profitable? Mural Oncology has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. Fate Therapeutics' return on equity of -50.95% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% Mural Oncology N/A -107.76%-87.57% Does the media prefer FATE or MURA? In the previous week, Fate Therapeutics had 13 more articles in the media than Mural Oncology. MarketBeat recorded 16 mentions for Fate Therapeutics and 3 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.85 beat Fate Therapeutics' score of 0.19 indicating that Mural Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Mural Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, FATE or MURA? Mural Oncology has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.05-$186.26M-$1.49-0.72Mural OncologyN/AN/A-$128.51M-$8.59-0.21 SummaryMural Oncology beats Fate Therapeutics on 8 of the 15 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.01M$2.48B$5.61B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-0.2122.0530.2825.74Price / SalesN/A742.42460.47115.79Price / CashN/A184.4138.2159.48Price / Book0.524.838.856.15Net Income-$128.51M$31.61M$3.25B$265.06M7 Day Performance11.32%4.55%3.72%2.60%1 Month Performance-28.92%5.69%5.86%2.83%1 Year Performance-43.81%12.71%30.34%25.58% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology3.1698 of 5 stars$1.77-1.1%$12.00+578.0%-44.2%$31.01MN/A-0.21119FATEFate Therapeutics4.066 of 5 stars$1.08+1.4%$3.83+256.6%-67.3%$123.20M$13.63M-0.72550News CoverageEarnings ReportAnalyst ForecastBHSTBioHarvest SciencesN/A$7.50-2.2%$13.67+82.2%N/A$123.19M$27.70M-15.00N/ANews CoverageEarnings ReportAnalyst RevisionGap UpCNTBConnect Biopharma3.3239 of 5 stars$2.20+7.8%$7.00+218.2%+83.8%$122.23M$26.03M0.00110News CoverageAnalyst ForecastShort Interest ↓Gap UpTARAProtara Therapeutics2.1556 of 5 stars$3.14-0.6%$20.50+552.9%+61.1%$121.14MN/A-1.8330Earnings ReportAnalyst RevisionSPROSpero Therapeutics4.0435 of 5 stars$2.14-5.5%$5.00+134.2%+62.3%$119.37M$47.98M-1.67150Earnings ReportOKYOOKYO Pharma3.0953 of 5 stars$3.15+0.8%$7.00+122.6%+164.0%$118.28MN/A0.007Positive NewsGap UpSAVACassava Sciences2.0656 of 5 stars$2.45+6.8%$54.50+2,129.0%-89.8%$118.12MN/A-1.6330News CoverageEarnings ReportGap DownCLYMClimb Bio3.5357 of 5 stars$1.75+2.6%$9.00+415.8%N/A$117.93MN/A-0.739Earnings ReportGap UpHigh Trading VolumeALTSALT5 Sigma0.6298 of 5 stars$6.75-1.0%N/A+321.6%$117.70M$12.53M0.00170Trending NewsOptions VolumeGap UpSKYESkye Bioscience1.6427 of 5 stars$3.79+4.4%$16.60+338.0%-27.3%$117.40MN/A-4.6211News CoverageAnalyst Forecast Related Companies and Tools Related Companies Fate Therapeutics Competitors BioHarvest Sciences Competitors Connect Biopharma Competitors Protara Therapeutics Competitors Spero Therapeutics Competitors OKYO Pharma Competitors Cassava Sciences Competitors Climb Bio Competitors ALT5 Sigma Competitors Skye Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access